PTO Not Qualified To Judge FDA Review of "Pipeline" Products - Barr
Executive Summary
Proposed legislation to reform the drug patent term restoration process could undercut FDA's "scientific judgements" by transferring undue authority to the Patent and Trademark Office, Sen. Leahy (D-Vt.) said during the Senate Judiciary committee's Aug. 4 hearing, "Pipeline Drugs: Proposed Remedies for Relief in S 1172."